Condition: Large B-cell Lymphoma · Sponsor: Genfleet Therapeutics (Shanghai) Inc.
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
This description comes directly from the study's public registry record.
Yolanda Zeng · +86 21 6882 1388 · yaozeng@genfleet.com
Always discuss trial participation with your own doctor first.
| Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute | Nanning, China | Recruiting |
| Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06375733